Chronic Obstructive Pulmonary Disease (COPD) is a progressive, long-term lung condition that can make it hard to breathe. The main cause of COPD is tobacco smoking1; however, other factors can contribute, such as:

  • Indoor and outdoor air pollution1,
  • Workplace exposures1,
  • Genetics.

The challenge of early COPD detection

Unfortunately, COPD is often diagnosed late, with Asthma + Lung UK reporting that the average wait for a diagnosis is 5 years2, with patient, provider, and structural factors contributing to this delay.

COPD is a disease that develops slowly, with symptoms like shortness of breath not appearing until significant lung damage has already occurred. This often presents in people’s 40s, 50s, or later3. And smokers often normalise their symptoms, accepting them because of their smoking. Another challenge is that early symptoms can overlap with other conditions, such as asthma, allergies, or other respiratory conditions4.

Early detection can significantly improve outcomes by allowing interventions that can reduce permanent lung damage, but with people brushing early symptoms off and a general lack of COPD awareness, it is very easy for early detection to be missed.

Hand holding a cigarette

Smoking exposure is the strongest modifiable risk factor

Smoking is believed to contribute to 90% of COPD cases1, with harmful chemicals in cigarette smoke damaging the lining of the lungs and airways. You don’t always have to be a smoker to be exposed to these harmful chemicals either; some research also suggests that passive smoking or exposure to other people’s cigarette smoke can increase your risk of COPD1.

This highlights the importance of understanding a person’s smoking history/exposure, because reducing the exposure will help to reduce the risk of developing COPD.

Why self-reported smoking history isn’t always enough

As the years have progressed, smoking has increasingly become viewed as a taboo behaviour that people may not want to fully admit to. This can make self-reporting unreliable, as individuals may underreport their smoking behaviour.

Smoking habits can change over time too; during stressful periods, smokers may smoke more excessively, or during periods of routine change, like holidays and time off work, people may smoke more.

This is why there is a need for more objective measures to fully understand a person’s smoking status, enabling healthcare professionals to better understand someone’s smoking exposure.

The role of carbon monoxide monitoring

Carbon monoxide (CO) is a harmful gas found in tobacco smoke which is inhaled when smoking. CO can be measured in exhaled breath, with higher levels indicating a person’s exposure to cigarette smoke.

CO monitoring devices like the Smokerlyzer® range offer healthcare professionals an objective tool to establish a person’s smoking status, initiating clinical conversations and supporting risk assessment.

A CO test with the Smokerlyzer® is quick and easy, offering a non-invasive way to assess CO exposure.

Smokerlyzer range

Earlier identification starts with better smoking assessment

Understanding smoking exposure is a key part of the puzzle, and having access to objective tools like the Smokerlyzer® to measure CO levels helps to identify high-risk individuals early and enable healthcare professionals to think about early signs of COPD and make the necessary interventions to improve patient outcomes.

To learn more about the Smokerlyzer® and how it can be a vital tool for assessing a person’s smoking status, visit the website here.

References

  1. NHS. Causes – chronic obstructive pulmonary disease (COPD) [Internet]. NHS. 2023 [cited 2026 Oct 14]. Available from: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/causes/
  2. A quarter of people with COPD waiting 5 years for a diagnosis | asthma + lung UK [Internet]. www.asthmaandlung.org.uk. [cited 2026 Oct 14]. Available from: https://www.asthmaandlung.org.uk/media/press-releases/quarter-people-copd-waiting-5-years-diagnosis
  3. NHS . Symptoms – chronic obstructive pulmonary disease (COPD) [Internet]. NHS. 2023 [cited 2026 Oct 29]. Available from: https://www.nhs.uk/conditions/chronic-obstructive-pulmonary-disease-copd/symptoms/
  4. Thornber K. Breaking barriers: Why COPD diagnosis is often delayed [Internet]. European Medical Journal. EMJ; 2025 [cited 2026 Oct 14]. Available from: https://www.emjreviews.com/respiratory/news/breaking-barriers-why-copd-diagnosis-is-often-delayed/

Asthma is a chronic lung condition affecting approximately 339.4 million people worldwide1, and when uncontrolled, it can be quite debilitating in everyday life. Despite modern-day medicine and the availability of effective treatments, approximately 39% of people with asthma remain uncontrolled1.

What do we mean by asthma control?

Asthma can cause various symptoms such as2:

  • Wheezing,
  • Coughing,
  • Shortness of breath,
  • Tight chest.

Asthma control can be measured by symptom frequency, night waking, reliever use, and activity limitations. Poor asthma control can be identified by increased symptoms, and controlled asthma can be recognised by minimal symptoms. Asthma is variable, so symptoms and control can change over time. Because of this, regular asthma reviews are important, even when patients feel fine. Reviews can help to evaluate the risk of future exacerbations and monitor treatment effectiveness.

Asthma symptoms, asthma control

What can good asthma control look like?

People with good asthma control should be able to carry out day-to-day activities with little to no limitations. However, it seems that people living with asthma have become accustomed to expecting symptoms daily and believe this to be normal. A European study found that out of 8,000 people, 80% considered their asthma to be controlled, when it was found that 45.1% had uncontrolled asthma3.

When asthma is under control, people should4:

  • Have few to no daytime symptoms,
  • Have reduced nighttime waking due to asthma,
  • Have less reliance on reliever medication,
  • Participate in exercise and sports.

More importantly, those with good asthma control should experience fewer exacerbations and fewer unscheduled healthcare appointments. Uncontrolled asthma can place a significant burden on healthcare systems; in 2023, the total direct cost to the NHS was believed to be over £1.5 billion5, emphasising the need for better asthma care.

Why symptoms don’t always tell the full story.

Airway Inflammation Infographic

In most people with asthma, inflammation can drive symptoms, but because airway inflammation is not visible, it is often overlooked. If a patient attends a routine asthma review and reports feeling fine, with little to no symptoms, airway inflammation can still be present, increasing the risk of future exacerbations. This demonstrates the need for objective testing in routine care to assess what cannot be seen: airway inflammation.

It is important to build a full picture of what’s happening in the airways instead of just asking about symptoms. This is where Fractional exhaled Nitric Oxide (FeNO) testing is vital to the asthma pathway.

What is FeNO testing6?

FeNO is a non-invasive biomarker associated with type 2 airway inflammation; it measures nitric oxide (NO) in exhaled breath. When inflammation is present in the airways, more NO is produced and can be measured in a person’s breath, helping to assess the level of airway inflammation. FeNO testing provides the missing piece of the puzzle as it can:

  • Support an asthma diagnosis,
  • Help clinicians make informed treatment decisions,
  • Identify poor adherence or inhaler technique,
  • Open up more informed conversations between patients and healthcare professionals.

Asthma is a variable condition, with symptoms, triggers and levels of airway inflammation potentially changing over time. Incorporating FeNO testing into routine asthma management can provide healthcare professionals with an objective measure of type 2 airway inflammation, helping them monitor changes over time and build a more complete picture of a patient’s asthma control.

As technology and understanding of FeNO have evolved, its role in asthma care has become increasingly recognised. In the UK, the 2024 joint asthma guideline from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS) and the Scottish Intercollegiate Guidelines Network (SIGN) incorporated FeNO testing into recommendations for the diagnosis and ongoing management of asthma7.

FeNO testing with the NObreath®.

The NObreath® is an FeNO device that has supported asthma diagnosis and management for over 15 years. Designed with the patient in mind, it provides adult and child test modes, making it suitable for most ages. Its compact, portable design makes it ideal for busy primary and secondary care settings, delivering accurate, reliable FeNO results trusted by healthcare professionals worldwide.

Good control is personal.

Everyone’s normal is different, so good asthma control isn’t about achieving a number; it should mean positive outcomes for the individual, which can translate to:

  • Sleeping through the night,
  • Exercising,
  • Not missing work or school because of symptoms,
  • Playing sport.

Good asthma control is about understanding symptoms and reducing future risk. Instead of focusing only on symptoms, consider inflammation. By providing an objective measurement of type 2 airway inflammation, FeNO testing adds the missing piece to the puzzle, helping healthcare professionals make more informed decisions and provide more personalised asthma care, ultimately improving patient outcomes.

To learn more about the role of FeNO testing in asthma management, read our blog here. For more information on FeNO testing with the NObreath®, visit the website here.

References

  1. Busse WW, Kraft M. Current unmet needs and potential solutions to uncontrolled asthma. European Respiratory Review [Internet]. 2022 Mar 31 [cited 2026 Sept 7];31(163). Available from: https://err.ersjournals.com/content/31/163/210176.long
  2. NHS. Asthma [Internet]. NHS. 2021 [cited 2026 Sept 7]. Available from: https://www.nhs.uk/conditions/asthma/
  3. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. npj Primary Care Respiratory Medicine [Internet]. 2014 June 12 [cited 2026 Sept 7];24(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373302/
  4. Asthma Zones: Signs of Controlled and Uncontrolled Asthma ǀ AAFA.org [Internet]. Asthma and Allergy Foundation of America. 2026 [cited 2026 Sept 7]. Available from: https://aafa.org/asthma/asthma-symptoms/asthma-control/
  5. Asthma + Lung UK [Internet]. 2023. [Cited September 2026]. Available from: https://www.asthmaandlung.org.uk/investing-breath-measuring-economic-cost-asthma-copd-uk-identifying-ways-reduce-it-through-better
  6. Asthma + Lung UK. FeNO test | Asthma + Lung UK [Internet]. www.asthmaandlung.org.uk. 2022 [cited 2026 Sept 7]. Available from: https://www.asthmaandlung.org.uk/symptoms-tests-treatments/tests/feno-test
  7. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024 [cited 2026 Sept 7]. Available from: https://www.nice.org.uk/guidance/NG245

Bedfont®, a world leader in breath analysis, has been recognised as one of Investec Direct Lending’s selected investments for 2025 following Keensight Capital’s majority investment in the company. The inclusion highlights Bedfont’s position as a leading UK medical technology innovator and reflects confidence from both Keensight and Investec in the company’s long-term growth strategy.

Why is this important?

Being featured in Investec Direct Lending’s Sustainability Report reflects confidence in Bedfont’s long-term growth and responsible approach to innovation. With a vision of a world where everyone has access to instant, non-invasive breath testing to aid medical diagnosis, Bedfont® continues to develop technologies that improve patient care while supporting a more sustainable future for healthcare. The investment from Keensight provides a strong foundation for the company’s continued innovation, international expansion and long-term sustainable growth.

Investec Recognises Bedfont Investment

For more than 50 years, Bedfont® has worked with healthcare professionals worldwide to deliver high-quality breath analysis solutions through technical innovation and professional business practices. Today, its products continue to support improved patient care across global healthcare markets, reinforcing Bedfont’s reputation as a trusted leader in non-invasive breath analysis.

Investec Recognises Bedfont Investment

Looking ahead.

The recognition also aligns with Bedfont’s commitment to responsible business practices, combining innovation with a long-term focus on improving patient outcomes, supporting its people and operating sustainably as the company continues to grow. As Bedfont® looks to the future, the company remains committed to advancing innovative, sustainable healthcare solutions and building on its successful portfolio of breath analysis devices. With Keensight’s support, Bedfont® is well positioned to continue its growth journey and expand its impact on patient care worldwide.

To learn more about Bedfont®, visit the website here. You can also read the full Investec Direct Lending Sustainability Report here.

Asthma is a chronic disease that affects millions worldwide, with many dying from the condition every year1. Asthma care has evolved over the years, but despite the advances, objectively assessing airway inflammation, the key driver of asthma, remains challenging in routine clinical practice.

Historically, asthma management has relied heavily on symptom reporting, but symptoms alone are unreliable indicators of airway inflammation. Inflammation in the airways cannot be seen, and whilst patients may appear clinically stable, airway inflammation may be present, necessitating the use of objective, measurable biomarkers.

FeNO – A non-invasive biomarker technology

Airway inflammation is associated with elevated levels of nitric oxide (NO) in exhaled breath, providing a measurable biomarker of eosinophilic inflammation known as Fractional exhaled Nitric Oxide (FeNO). Using a FeNO device, clinicians can rapidly assess airway inflammation through a non-invasive test that delivers real-time results to support asthma diagnosis, monitoring, and treatment optimisation.

Evolution of FeNO Testing

The evolution of FeNO technology

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence technology to measure it, detecting NO through light emitted during a chemical reaction. This method provided high sensitivity and accuracy but proved very costly due to the need for regular maintenance and calibration, limited accessibility, and the specialist training required to operate it. It was clear that early FeNO technology demonstrated clinical value but lacked scalability.

In recent years, this has advanced to electrochemical sensor technology, enabling a new generation of portable FeNO devices, including the NObreath®, whilst still matching the gold-standard chemiluminescence technology.

Modern FeNO devices using electrochemical sensors have decentralised diagnostics, providing a portable respiratory diagnostic option which is easy to integrate into point-of-care workflows. The devices are easy to use and no longer require specialist training, making them a more cost-effective option in respiratory diagnostics.

How point-of-care FeNO testing changes clinical practice

Thanks to continuous innovation, FeNO devices are now accessible at the point of care, enabling faster clinical decision-making, improved monitoring capabilities, and more personalised asthma management. This evolution reflects a broader shift toward decentralised, non-invasive diagnostic technologies designed to support earlier detection and more proactive respiratory care.

FeNO testing – Ease of use

Recent developments in FeNO devices have focused on usability, workflow efficiency, and accessibility. For example, the NObreath®, now in its 2nd generation, is a portable FeNO device which pioneered the exhalation-only manoeuvre. Helping to improve asthma care for over 15 years, the device is suitable for both adults and children, the test is easy to complete and provides a flow incentive to ensure a flow rate of 50 ml/s, yielding an accurate result. Providing instant results, FeNO testing supports efficient point-of-care workflows and faster clinical decision-making.

The future of respiratory diagnostics

The inclusion of FeNO testing in clinical guidelines has increased throughout the years, with the 2024 UK guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN) recommending FeNO as a first-line test to aid asthma diagnosis and management2.

This marks a major shift in asthma care, with a growing emphasis on biomarker-led approaches and more personalised treatment strategies to improve patient outcomes. As respiratory diagnostics become increasingly accessible beyond hospitals and specialist centres, more patients can benefit from advanced technologies through primary care, community clinics, and outpatient respiratory services. Reflecting this trend, Intermedical UK, the exclusive UK distributor of the NObreath® FeNO device, has now installed more than 3,000 devices across the UK, including over 1,200 since the 2024 guideline update, highlighting the rapid adoption of FeNO testing in routine clinical practice.

FeNO testing offers a non-invasive option to aid diagnosis and monitoring of asthma, making biomarker testing more accessible and decentralising respiratory monitoring. Continued innovation in this technology may even expand to home monitoring in the future.

NObreath® Evolution of FeNO Testing

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Written by Carol Stonham MBE

Carol Stonham MBE - Love Your Lungs Week

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the NObreath® is as follows:

The 2nd generation NObreath® is a breath nitric oxide (NO) test system intended to measure fractional exhaled nitric oxide (FeNO) in parts per billion (ppb) in exhaled breath.

FeNO measurement is taken to evaluate airway inflammation and should be used in conjunction with other clinical and laboratory evaluations where appropriate when making a diagnosis or treatment plan. The measurements are intended for interpretation by healthcare professionals and for us in a healthcare environment, where paediatric and adult patients will complete measurements under supervision.

Love Your Lungs Week and Asthma

For many people lungs don’t really feature in their daily self-awareness despite the vital work they do. They are there in the background doing their job. For many people Love your Lungs week might just make them think about what a good job their lungs are doing and maybe look for ways of encouraging them to stay healthy – avoiding pollution, not smoking or vaping and getting regular exercise in for example.

For those people with asthma Love Your Lungs week might have a different emphasis. Asthma symptoms, whether minor or more dramatic, will certainly make a person aware of their breathing. Good asthma care can help to keep the symptoms under control and avoid bouts of acute symptoms.

Good asthma care starts with an accurate diagnosis. Historically an asthma diagnosis was made on assessment of symptoms, perhaps some lung function testing, and response to treatment. Evidence shows us we sometimes got it wrong using this approach 1. The current joint UK guidelines from British Thoracic Society (BTS), Scottish Intercollegiate Network (SIGN) and National Institute for Health and Care Excellence (NICE)2 have moved to basing a diagnosis of asthma on assessment of symptoms and history that is supported by objective testing. Fractional exhaled nitric oxide (FeNO) is the first recommended test based on clinical accuracy and cost effectiveness. A raised FeNO is an indicator of eosinophilic airway inflammation which is commonly seen in most types of asthma when it is not adequately treated with inhaled corticosteroids (ICS).

Love Your Lungs Week

Once an accurate diagnosis has been made the person being diagnosed needs to understand what asthma is, what is happening in their lungs, and how their treatment works. There are no agreed education sessions for people newly diagnosed with asthma as there are for those with diabetes.

As asthma is a variable condition, understanding these features support the person to adjust medication to control symptoms and self-manage their condition. Healthcare input is minimal in someone with asthma – an annual review is usually the only planned touch point; others tend to be when the symptoms are poorly controlled. Most healthcare professionals will use a diagram or airway model to explain asthma but the addition of FeNO is a useful tool to demonstrate inflammation especially in the symptomatic person. It helps both practitioner and patient to understand what is happening in the lungs – a measured objective marker demonstrating inflammation.

Why Objective Assessment Remains Important

Many people with a long-term health condition will become so used to the symptoms they experience and the regular use of treatment4. This is seen in some people with asthma – they accept that they have asthma therefore they accept a wheeze or cough4, they stop taking regular ICS treatment and instead rely on a rescue inhaler to treat symptoms as they arise4, or they might continue treatment but fall into bad habits and use their inhaler incorrectly5. In all of these cases measuring FeNO is helpful to assess the underlying airway inflammation, to demonstrate suboptimal control of airway inflammation, and to base ongoing treatment decisions which may require a change of medication, a change of inhaler device or commonly, simply a reminder that asthma treatment needs to be taken regularly with good technique.

The NObreath® FeNO Device

Love Your Lungs Week

FeNO testing with the NObreath® is a quick and easy non-invasive way to objectively measure airway inflammation. With adult and child test modes, the NObreath® is suitable for all settings thanks to its accuracy and portability. Featuring an exhalation-only manoeuvre, the test is easy to do and can help to improve asthma care, allowing healthcare professionals to tailor asthma treatment effectively.

Love Your Lungs for those with asthma should focus on getting the treatment right and taking it effectively and regularly so that the lungs can get on doing their job without reminding the person they have asthma at all. Of course, that will also include the general measures that everyone else will be considering – avoiding pollution, avoiding smoking and vaping, and getting regular exercise in, but good asthma care will support activity without a symptom burden. 

References:

  1. Aaron SD, Vandemheen KL, FitzGerald JM, Ainslie M, Gupta S, Lemière C, Field SK, McIvor RA, Hernandez P, Mayers I, Mulpuru S. Reevaluation of diagnosis in adults with physician-diagnosed asthma. JAMA. 2017;317(3):269-79.
  2. National Institute for Health and Care Excellence. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245) [Internet]. London: NICE; 2024 [cited 2026 18 Jun]. Available from: https://www.nice.org.uk/guidance/ng245
  3. Patel S, Huang M, Miliara S. Understanding treatment adherence in chronic diseases: challenges, consequences, and strategies for improvement. Journal of Clinical Medicine. 2025 Aug;14(17):6034. DOI: 10.3390/jcm14176034.
  4. Canonica GW, Domingo C, Lavoie KL, Kaliasethi A, Khan SQ, Majumdar A, Fulmali S. Asthma patients’ and physicians’ perspectives on the burden and management of asthma: post-hoc analysis of APPaRENT 1 and 2 to assess predictors of treatment adherence. Respiratory medicine. 2024;227:107637.
  5. Bosnic-Anticevich S, Bender BG, Shuler MT, Hess M, Kocks JW. Recognizing and tackling inhaler technique decay in asthma and chronic obstructive pulmonary disesase (COPD) clinical practice. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(8):2355-64.

Small Intestinal Bacterial Overgrowth (SIBO) is a gastrointestinal condition where an abnormal number of bacteria is found in the small intestine. Whilst small amounts of bacteria are normal, higher levels can cause uncomfortable digestive issues. SIBO can impact nutritional absorption and affect hydration. In this article, we will take a closer look at the impact of SIBO and how Hydrogen and Methane Breath Testing (HMBT) can aid in a diagnosis.

What is SIBO?1

SIBO is a condition characterised by elevated bacterial levels in the small intestine. This excess amount of bacteria ferments food and interferes with digestion. Common causes of SIBO include:

  • Motility issues: Slowed gut movement from conditions like irritable bowel syndrome (IBS), diabetes, or surgery.
  • Low stomach acid: Reduced acid allows bacteria to survive and travel to the small intestine.
  • Structural problems: Adhesions, scarring, or bowel surgery.

There are different types of SIBO, categorised by the primary gas produced. Hydrogen-dominant, methane-dominant and mixed SIBO are the most common forms. SIBO causes various uncomfortable symptoms, such as:

  • Bloating,
  • Abdominal pain,
  • Diarrhoea or constipation,
  • Excess gas,
  • Fatigue.

These symptoms can significantly impact a person’s quality of life, underscoring the need for an accurate diagnosis.

Why diagnosis matters.2,3

Symptoms of SIBO can overlap with many other gut conditions, mimicking conditions like IBS, Chron’s disease and coeliac disease. Given the significant overlap in symptoms, a definitive diagnosis is crucial. SIBO is frequently misdiagnosed, and this can lead to inappropriate treatments and ongoing symptoms; an early diagnosis can improve patient outcomes. The primary test for SIBO is a non-invasive HMBT.

What is HMBT?4

A Hydrogen and Methane Breath Test (HMBT) is a non-invasive diagnostic method for measuring hydrogen and methane concentrations in exhaled breath. As approximately 30%–62% of the adult population are methane producers5, there is a clear need for HMBT methods that reliably detect both gases.

Prior to the test, the patient must follow a strict protocol that includes a fasting period. On the day of the test, the patient will be asked to do the following:

  • Drink a sugar solution like lactulose or glucose.
  • Exhale into an HMBT device at certain timed intervals.

Hydrogen and methane are the gases produced when bacteria ferment food prematurely in the small intestine. High levels of these gases can indicate elevated bacterial levels and support a diagnosis of SIBO.

What happens after diagnosis?6

Once a diagnosis has been confirmed, SIBO can be treated by either:

  • Antibiotics,
  • Dietary changes,
  • Addressing the root cause.

A HMBT allows healthcare professionals to target treatment options, providing the best outcome for the patient.

SIBO is a common condition, but it is often overlooked due to overlap in symptoms. It can affect nutrient absorption, leading to vitamin deficiencies, and can impact hydration through its symptoms. It is vital that you consult with a healthcare professional for an accurate diagnosis. By providing a HMBT for an accurate diagnosis, healthcare professionals can tailor treatment to relieve symptoms, providing better outcomes for patients.

The Gastrolyzer® range by Bedfont® Scientific Limited

The Gastrolyzer® range of HMBT devices is designed to aid the diagnosis of various gastrointestinal conditions, such as SIBO and carbohydrate malabsorption.

The Gastro+™ is a portable, handheld device that measures hydrogen gas levels in exhaled breath. Breath testing can be performed with mouthpieces or by facemask, making it a perfect solution for infants and elderly patients who may struggle to hold their breath before exhaling.

The GastroCH4ECK® is a desktop HMBT device that measures hydrogen and methane gas levels in exhaled breath. Remote testing can be performed with the GastroCH4ECK® using breath bags for accurate, reliable results.

For more information on HMBT and how tools like the Gastrolyzer® are aiding gastrointestinal investigations, visit the educational portal here.

References

  1. SIBO Symptoms & Diagnosis | Digestive Health | Royal Bucks [Internet]. The Royal Buckinghamshire Hospital. 2025 [cited 2026 Jan 21]. Available from: https://www.royalbucks.co.uk/conditions-and-symptoms/small-intestinal-bacterial-overgrowth/
  2. Shah A, Thite P, Hansen T, Kendall BJ, Sanders DS, Morrison M, et al. Links between celiac disease and small intestinal bacterial overgrowth: A systematic review and meta‐analysis. Journal of Gastroenterology and Hepatology [Internet]. 2022 Oct 1;37(10):1844–52. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795979/
  3. ‌Goździewska M, Łyszczarz A, Kaczoruk M, Kolarzyk E. Relationship between SIBO and other bowel diseases and a common eating pattern for them. Part III. Annals of Agricultural and Environmental Medicine. 2024 Sep 19;31(3):322–8.
  4. Hydrogen/Methane Breath Testing for SIBO and Malabsorption [Internet]. Bsg.org.uk. 2024. Available from: https://www.bsg.org.uk/clinical-resource/agip-protocol-for-hydrogen-methane-breath-testing
  5. Sahakian AB, Jee SR, Pimentel M. Methane and the Gastrointestinal Tract. Digestive Diseases and Sciences [Internet]. 2009 Oct 15;55(8):2135–43. Available from: http://image.sciencenet.cn/olddata/kexue.com.cn/upload/blog/file/2010/1/2010123203248875447.pdf
  6. Gastroadmin. Management of Small Intestinal Bacterial Overgrowth – SIBO [Internet]. London Gastroenterology Centre. 2019. Available from: https://www.gastrolondon.co.uk/management-of-small-intestinal-bacterial-overgrowth-sibo/

Tobacco kills more than 7 million people each year, including an estimated 1.6 million non-smokers exposed to second-hand smoke.1 It is estimated that tobacco costs the global economy more than $1.4 trillion a year in healthcare costs and lost productivity.2 This World No Tobacco Day, we are going to explore the appeal behind smoking tobacco and the healthcare burden it causes.

What is World No Tobacco Day?3

World No Tobacco Day is a global awareness event, held every year on the 31st May by the World Health Organisation (WHO). The event was created to draw global attention to the tobacco epidemic and the preventable deaths and diseases it causes. Each year follows a new theme; the theme for 2026 is Unmasking the appeal – countering nicotine addiction. Whilst global tobacco use has declined in recent years, its burden remains devastating.

The appeal: Why tobacco still attracts users.

Cigarette in a hand

Whilst evidence does not support this, smoking is still widely perceived as a stress reliever, with studies indicating that between 36-43% of people believe smoking helps manage stress, anxiety and depression. The truth is, smoking actually increases tension and lowers mental health in the long run.4

Marketing tactics have changed over the years with the introduction of vapes, flavoured products, and targeting youth and young adults, especially in low-income communities and regions with weaker tobacco regulations.

Together, these psychological misconceptions and evolving marketing strategies create a powerful and carefully engineered appeal. Nicotine products are framed as tools for coping, symbols of independence, or fashionable accessories, rather than addictive substances. These influences normalise use, particularly among younger and more vulnerable populations, making tobacco appear not only acceptable but desirable.

The health burden: What tobacco really costs.

Smoking tobacco has a direct impact on health and is linked to diseases like:5

  • Lung cancer,
  • Chronic obstructive pulmonary disease (COPD),
  • Coronary artery disease,
  • Stroke.

This doesn’t just impact the smokers themselves; non-smokers are also affected by second-hand smoke, leading to a significant impact on healthcare systems worldwide.

Smoking-related hospital admissions and care in the UK alone cost the NHS £1.9 billion each year, signifying an urgent need for change.6

What needs to change?

There are many contributing factors that could change and improve outcomes worldwide, and whilst there are already various initiatives in place, such as:

  • Plain packaging,
  • Smoke-free zones,
  • Less advertisement.

More can be done across the board to remove the appeal.

Awareness campaigns like World No Tobacco Day help to raise awareness of the significant impact smoking can have on health and economic costs. Additionally, smoking cessation programmes can provide support for those looking to quit smoking. These services can educate smokers on the long-term benefits of quitting smoking as well as highlight tools which can aid a quit attempt. One of those tools is carbon monoxide (CO) monitoring.

What is CO monitoring?

Taking a CO test with the Smokerlyzer

When someone smokes tobacco, they inhale CO, which enters their bloodstream and reduces oxygen delivery around the body.7 A CO monitoring device like the Smokerlyzer® measures CO levels in a person’s exhaled breath. The Smokerlyzer® is widely used across the world as a motivational tool to aid a quit-smoking attempt. Seeing CO levels drop empowers smokers to continue their quit-smoking journey.

Smokerlyzer Range

A 2012 study found that people who used a CO monitoring device reported feeling more motivated to quit smoking. Participants described how seeing their CO levels decrease over time provided clear, tangible evidence that their efforts were making a real difference. This immediate, visible feedback appeared to strengthen their commitment to quitting by reinforcing the health benefits of staying smoke-free and encouraging them to keep going, especially during moments of doubt or temptation.8

World No Tobacco Day 2026 is highlighting how the appeal to nicotine and tobacco addiction is engineered and not accidental. With healthcare and economic costs rising, it is vital that more is done to tackle the tobacco epidemic.

To learn more about the support available to aid a quit smoking attempt, visit the NHS website here.

To find out more about the Smokerlyzer® range and how it is helping people quit smoking for good, visit the website here.

References

  1. World Health Organization. Tobacco [Internet]. World Health Organization. World Health Organization; 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco
  2. ‌US$ 1.4 trillion lost every year to tobacco use – New tobacco tax manual shows ways to save lives, money and build back better after COVID-19 [Internet]. www.who.int. Available from: https://www.who.int/news/item/12-04-2021-1.4-trillion-lost-every-year-to-tobacco-use-new-tobacco-tax-manual-shows-ways-to-save-money-and-build-back-better-after-covid-19
  3. ‌World. World No Tobacco Day 2026: Unmasking the appeal – countering nicotine and tobacco addiction [Internet]. Who.int. World Health Organization: WHO; 2025. Available from: https://www.who.int/news/item/17-10-2025-world-no-tobacco-day-2026–unmasking-the-appeal—countering-nicotine-and-tobacco-addiction
  4. ‌Perski O, Theodoraki M, Cox S, Kock L, Shahab L, Brown J. Associations between smoking to relieve stress, motivation to stop and quit attempts across the social spectrum: A population survey in England. Kaye JT, editor. PLOS ONE [Internet]. 2022 May 17;17(5):e0268447. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0268447
  5. ‌ASH. Smoking and Other Health Conditions – ASH [Internet]. ASH. 2025. Available from: https://ash.org.uk/resources/view/smoking-and-other-health-conditions
  6. ‌Action on Smoking and Health. Latest figures show cost of smoking in England up 25% to at least £21.8 billion [Internet]. ASH. 2024. Available from: https://ash.org.uk/media-centre/news/press-releases/latest-figures-show-cost-of-smoking-in-england-up-25-to-at-least-21-8-billion
  7. ‌Raub JA, Benignus VA. Carbon monoxide and the nervous system. Neuroscience and Biobehavioral Reviews [Internet]. 2002 Dec 1;26(8):925–40. Available from: https://pubmed.ncbi.nlm.nih.gov/12667497/
  8. ‌Beard E, West R. Pilot study of the use of personal carbon monoxide monitoring to achieve radical smoking reduction. Journal of Smoking Cessation. 2012 Jun;7(1):12-7.

In 2019, 262 million people worldwide had asthma, with 455,000 deaths from the chronic condition1, stark figures that highlight asthma control still needs improvement. Most people living with asthma believe that no physical symptoms mean their asthma is controlled, but this is sadly not always the case. Airway inflammation is the underlying cause of asthma, something that cannot be seen and not always felt.

Many asthma patients feel fine until they don’t. Objectively measuring airway inflammation with Fractional exhaled Nitric Oxide (FeNO) testing is a vital way to prevent exacerbations and improve overall asthma care.

Airway Inflammation Infographic - Advancements in FeNO Testing

What is FeNO and why does it matter2?

When airways are inflamed, they produce excess nitric oxide (NO), a gas that can be measured by performing a FeNO test. A FeNO test provides insight into a person’s airway inflammation by measuring NO levels in exhaled breath.

  • High FeNO levels indicate eosinophilic airway inflammation. The higher the reading, the more severe the inflammation is.

By measuring airway inflammation, healthcare professionals can use the results to aid an asthma diagnosis and tailor treatment appropriately.

Limitations of traditional asthma monitoring.

Taking a FeNO test with the NObreath - Advancements in FeNO Testing

Traditionally, clinicians have relied on patients relaying their symptoms, which doesn’t always give the full picture of a person’s asthma. Many people believe that because they have asthma, they should have a cough and they should have a wheeze, and they downplay their symptoms.

Providing a FeNO test at regular asthma reviews empowers healthcare professionals to detect airway inflammation early, allowing them to monitor medication response and personalise treatment. This ultimately can catch an exacerbation early and get patients back on track with well-controlled asthma.

Additionally, medication adherence rates range from 30% to 70%3. A patient may report taking their medication regularly and using the correct technique; however, a quick, easy FeNO test can reveal poor adherence. Showing a patient their airway inflammation can create an opportunity to discuss and reinforce the importance of good adherence and technique.

Recent advancements in FeNO testing.

NObreath device - Advancements in FeNO Testing

In the 1990s, researchers found that FeNO served as a non-invasive biomarker of airway inflammation and used chemiluminescence to measure it. This method proved very costly due to regular maintenance and calibration, and difficult to access because of the machines’ size and the specialist training required.

In recent years, this has advanced to electrochemical sensor technology, enabling more cost-effective, portable FeNO devices like the NObreath®, whilst still matching the gold-standard technology of chemiluminescence. Thanks to continuous innovation, FeNO devices are now accessible at the point of care and provide instant results, improving patient outcomes.

To learn more about chemiluminescence and electrochemical sensor technology, read our article here.

In the late 1990s, FeNO began to appear in international clinical practice guidelines for asthma, and the American Thoracic Society (ATS) officially recommended its use to assess airway inflammation in adults and children in 20114.

Since then, FeNO testing has been recommended in asthma guidelines across the world, with the most recent joint guidance from the National Institute for Health and Care Excellence (NICE), the British Thoracic Society (BTS), and the Scottish Intercollegiate Guidelines Network (SIGN), recommending FeNO as a first-line test for asthma diagnosis5.

To learn more about the global guidelines on asthma care and management, read our article here.

The NObreath® FeNO device

The NObreath® was developed in 2008, designed with healthcare professionals and patients in mind. It provides a non-invasive, fairly priced option for FeNO testing, making it more accessible to healthcare providers worldwide.

Featuring an adult and child test mode, the NObreath® is suitable for all settings thanks to its accuracy and portability. It requires an exhalation-only manoeuvre, making it a quick and easy test to take for both adults and children.

The device was designed with the patient in mind and features multiple flow incentive screens. These incentive screens not only engage the patient, but they also ensure a correct flow rate of 50 ml/s, providing an accurate test result.

To learn more about FeNO testing with the NObreath®, visit the website here.

Child test with the NObreath - Advancements in FeNO Testing

Many deaths from asthma are thought to be preventable, meaning better asthma care is needed. Advances in FeNO testing have been instrumental in improving asthma control, and with increasing recognition in global asthma guidelines, FeNO testing can make a difference.

To learn more about Bedfont® Scientific Limited, world leaders in breath analysis with over 49 years of expertise in the medical device industry, visit the website here.

References

  1. World Health Organization. Asthma [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma
  2. NHS England. NHS Accelerated Access Collaborative» Fractional Exhaled Nitric Oxide (FeNO) [Internet]. www.england.nhs.uk. 2025. Available from: https://www.england.nhs.uk/aac/what-we-do/innovation-for-healthcare-inequalities-programme/rapid-uptake-products/fractional-exhaled-nitric-oxide/
  3. ‌Improving adherence in Asthma treatment | Cambridge Network [Internet]. Cambridgenetwork.co.uk. 2024. Available from: https://www.cambridgenetwork.co.uk/news/improving-adherence-asthma-treatment
  4. ‌Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. American journal of respiratory and critical care medicine [Internet]. 2011;184(5):602–15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/21885636/
  5. National Institute for Health and Care Excellence. Overview | Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) | Guidance | NICE [Internet]. Nice.org.uk. NICE; 2024. Available from: https://www.nice.org.uk/guidance/NG245

Over 28 million people in the United States (US) have asthma1,2, with the condition named as the leading chronic disease in children, affecting approximately 4.9 million under the age of 182,3. In the US, asthma is one of the most common and costly diseases, and these stark figures highlight why asthma still matters, even in 2026. This Asthma and Allergy Awareness Month, we are exploring the prevalence of asthma and how advancing technology can make a difference.

Asthma and Allergy Awareness Month

Asthma places a significant burden on healthcare and the economy, with annual economic costs between 2008 and 2013 contributing to:

  • $3 billion in losses due to missed work and school days,
  • $29 billion due to asthma-related mortality,
  • $50.3 billion in medical costs.

The numbers prove that asthma is common, but it is important to remember that this chronic condition is also manageable; however, outcomes are not equal, and certain populations are disproportionately affected. These disparities are shaped by a combination of structural, social, biological, and behavioural factors. Structural inequities, such as5:

  • Systemic racism,
  • Residential segregation,
  • Discriminatory policies,

Often influence the conditions in which people live, work, and access care. These, in turn, affect social determinants like income, education, housing quality, environmental exposures, and access to healthcare. While biological factors such as genetics and individual behaviours like smoking or medication adherence play a role, it is these broader social and structural inequities that largely drive unequal asthma outcomes across populations.

The hidden problem: Poor asthma control

Millions of people are diagnosed with asthma, with many of them not having the condition well managed. It is estimated that 44% of children with asthma have uncontrolled asthma6, which can lead to exacerbations and severe asthma attacks.

Many asthma patients rely heavily on rescue inhalers, which relieve the immediate symptoms but do not address the underlying airway inflammation. This quick relief can make patients feel in control of their asthma, but without addressing the root cause, asthma remains uncontrolled beneath the surface.

Another contributor to poorly controlled asthma is misdiagnosis. Asthma is not a single condition; it can be allergic/eosinophilic or non-eosinophilic. If the asthma is not diagnosed correctly, this can lead to ineffective or over/under treatment. If the underlying asthma type isn’t properly diagnosed, the treatment cannot be matched to the disease type.

Additionally, a lack of objective measurement in routine care can affect asthma control. Traditionally, asthma management has relied on:

  • Symptoms,
  • Patient recall,
  • Peak flow.

The problem with just focusing on these points is that clinicians may over- or underestimate control, which leads to escalating or reducing treatment inappropriately. Symptoms do not always reflect underlying inflammation and may lead to missed opportunities for early intervention.

Better Asthma Care

This is where better access to objective, point-of-care tools, such as Fractional exhaled Nitric Oxide (FeNO) testing, is needed. Without objective measurement, asthma care often relies on what can be seen and heard, not on what’s happening at the inflammatory level inside.

What is FeNO testing7?

A FeNO test is a quick, easy, non-invasive way to measure airway inflammation, specifically eosinophilic inflammation. When airways are inflamed, higher levels of nitric oxide (NO) are produced. This gas can be detected in exhaled breath, with higher levels indicating inflammation, making FeNO testing a vital tool for asthma care and management.

FeNO Testing with the NObreath®

With FeNO providing a non-invasive, quick point-of-care test, it can help identify type 2 inflammation and predict steroid responsiveness, helping clinicians see inflammation that symptoms alone cannot reveal.

How FeNO improves decision-making

FeNO fits into the whole asthma pathway; it’s not just a diagnostic tool; it can also help treat and manage asthma. Diagnosing and managing this chronic condition isn’t always straightforward, and in the past, healthcare professionals have relied on guesswork. FeNO testing changes that, it can:

  • Support a diagnosis of asthma,
  • Guide inhaled corticosteroid (ICS) use,
  • Monitor medication adherence,
  • Predict exacerbation risk,
  • Reduce unnecessary medication escalation.
Child taking a FeNO test

FeNO is recognised in global guidelines for asthma care and management, with the ATS/ERS guidance positioning FeNO as a practical tool to support diagnosis, guide anti-inflammatory treatment, and monitor airway inflammation, helping clinicians move from symptom-based to more objective asthma care8.

Expanding access to FeNO testing

Objective testing has the potential to transform asthma care, but access remains a challenge. Limited availability outside specialist centres, time constraints in primary care, and geographic inequalities have all contributed to the underuse of tools such as FeNO. The result is a gap between what is possible and what is delivered in everyday care. Advances in technology only matter if people can access them.

Bedfont® Scientific Limited, an innovative MedTech company based in the UK with nearly 50 years of experience in medical breath analysis, has been improving asthma care and management worldwide for over 15 years with its NObreath® FeNO device. Working closely with its US distributor, coVita™, it has been working hard to improve access to FeNO testing by providing a fairly priced, low-maintenance FeNO device.

In 2025, the NObreath® became the allergists’ FeNO device of choice in the US, with Allergy Partners offering FeNO testing with the NObreath® through more than 125 locations in over 20 states. This partnership ensures that FeNO testing is being integrated into routine care, not just specialist settings, allowing more patients to get tested closer to home.

The future of asthma care

This Asthma and Allergy Awareness Month, we want to focus on how early intervention can lead to better long-term outcomes for asthma patients. Advances in technology mean that objective testing, such as FeNO, is more widely accessible, which is vital as biomarker-driven care becomes the standard. FeNO devices like the NObreath® provide clinicians with more insight into underlying inflammation that cannot be seen, enabling improved patient care.

To learn more about the NObreath® FeNO device and how it is improving precision in asthma care, visit the website here.

NObreath® FeNO device

References

  1. NCHS/DHIS. NHIS Adult Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Adult-Summary-Health-Statistics/25m4-6qqq/about_data
  2. ‌NCHS/DHIS. NHIS Child Summary Health Statistics [Internet]. Cdc.gov. 2021. Available from: https://data.cdc.gov/National-Center-for-Health-Statistics/NHIS-Child-Summary-Health-Statistics/wxz7-ekz9/about_data
  3. ‌Ferrante G, La Grutta S. The Burden of Pediatric Asthma. Frontiers in Pediatrics [Internet]. 2018 Jun 22;6(186):1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023992/
  4. ‌Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, 2008–2013. Annals of the American Thoracic Society [Internet]. 2018 Mar;15(3):348–56. Available from: https://pubmed.ncbi.nlm.nih.gov/29323930/
  5. ‌Asthma and Allergy Foundation of America. Asthma Disparities in America [Internet]. Asthma & Allergy Foundation of America. 2020. Available from: https://aafa.org/asthma-allergy-research/our-research/asthma-disparities-burden-on-minorities/
  6. ‌CDC Archives [Internet]. archive.cdc.gov. Available from: https://archive.cdc.gov/#/details?url=https://www.cdc.gov/asthma/asthma_stats/uncontrolled-asthma-children-2018-2020.htm
  7. ‌What is a FeNO Test? [Internet]. Aaaai.org. 2021. Available from: https://www.aaaai.org/Tools-for-the-Public/Conditions-Library/Asthma/What-Is-A-FeNO-Test
  8. ‌Murphy RC, Zhang P, Tejwani V, Khatri SB, Hallstrand TS, Ruminjo JK, et al. Summary for Clinicians: Clinical Practice Guideline for the Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma. Annals of the American Thoracic Society. 2022 Oct;19(10):1627–30.

Written by Dr Jafar Jafari, GI Cognition

This article reflects the opinions of a healthcare professional. The views expressed are their own. The intended use for the GastroCH4ECK® is to aid in the diagnosis of the following disorders:

  • Lactose Intolerance,
  • Small Intestinal Bacterial Overgrowth (SIBO).

Hydration and nutrition are often discussed as two separate topics. In reality, they work together every single day inside the digestive system. What we drink influences how comfortably we tolerate fibre, how easily our bowels move, and how efficiently our digestive system works. What we eat influences digestion, gas production, stool pattern, energy levels, and symptoms such as bloating or abdominal discomfort.

A simple way to think about this relationship is to imagine trying to mix ingredients in a completely dry container. Nothing moves properly. The contents simply sit there. Digestion works in a similar way: without adequate fluid, the digestive system struggles to move food smoothly through the gut. Hydration provides the medium in which digestion happens, while nutrition provides the materials the body, and the microbes in our gut, need to function.

But how do we know whether our gut is responding well to what we eat and drink? Interestingly, one of the most informative signals can come from something we rarely think about: our breath.

Your Breath as a “Thermometer” for the Gut1

One of the reasons I became so interested in hydrogen–methane breath testing (HMBT), and ultimately wrote a book about it The Essential Guide to Hydrogen and Methane Breath Testing, the book offers a unique window into how our digestive system is functioning.

Human tissues do not produce hydrogen or methane gases. These gases are produced when microorganisms in the gut ferment carbohydrates that escape digestion. Some of this gas enters the bloodstream and eventually reaches the lungs, where it is exhaled in our breath. By measuring hydrogen and methane in breath samples over time, clinicians can gain insight into microbial fermentation patterns in the gut.

In a way, breath testing acts like a thermometer for gut activity. Just as a thermometer shows how the body is responding to infection or inflammation, breath testing can reveal how gut microbes are responding to the food and drink we consume.

The interesting point is that this signal often appears much earlier than other markers of health. For example, nutritional deficiencies such as low iron or low vitamin B12 can take months or even years to develop before they are detected in blood tests. But changes in microbial fermentation can occur much more quickly, reflecting the daily interaction between diet, hydration, gut motility and microbial activity.

In that sense, microbial fermentation may provide one of the earliest signals that something in our digestive habits is not working well.

Why “Healthy Foods” Sometimes Cause Symptoms

One of the most common questions people ask is: “Why do I react to foods that are supposed to be healthy?”

  • The answer is surprisingly simple: healthy does not always mean symptom-free.

Foods such as fruit, beans, lentils, whole grains and many vegetables are rich in fibre and nutrients2. These foods are beneficial for long-term health and support the growth of beneficial microbes in the gut.

However, they are also fermentable. For people with slower gut movement, increased microbial activity in the small intestine, or heightened gut sensitivity, fermentation of these foods may produce more gas than the body comfortably tolerates1.

This does not mean those foods are harmful or should be permanently avoided. It simply means that digestion sometimes requires a more personalised approach, including attention to portion size, timing, food combinations and underlying digestive function. Understanding these patterns is where breath testing can sometimes be helpful.

Hydration: The Forgotten Partner of Fibre

Another question I frequently hear is whether drinking more water can help symptoms such as constipation or bloating. Hydration alone is rarely a complete solution, but it plays a crucial role in maintaining normal digestive function.

Adequate fluid intake supports healthy bowel movement and gut motility. When the body is dehydrated, the intestines absorb more water from the stool, making it harder and more difficult to pass.

Hydration also becomes particularly important when people increase fibre intake. Fibre and fluid work together. Increasing fibre rapidly without increasing fluid can sometimes make symptoms feel worse, especially in people with sensitive digestive systems.

For most adults, general NHS guidance suggests roughly 6 to 8 glasses of fluid per day3, though individual needs vary depending on activity level, environment and health status. A simple daily indicator of hydration is urine colour, pale yellow generally indicates adequate hydration3.

Another useful indicator of digestive health is the Bristol stool chart4, which describes stool consistency. It is a simple but surprisingly helpful way of monitoring how well the digestive system is functioning4.

These simple daily observations, hydration, stool pattern, and symptoms, can act as basic “thermometers” of gut health. Breath testing simply provides a more advanced version of this thermometer, offering deeper insight into microbial fermentation patterns, when the basic thermometers are not sufficient anymore1.

Why Testing Before Treatment Matters1

When people experience persistent digestive symptoms, they often feel tempted to experiment with probiotics, restrictive diets, or various supplements. Trying something new can feel proactive. However, in some situations this approach may not address the underlying cause and can occasionally make symptoms worse.

For example, if someone already has excessive microbial activity in the small intestine, adding more bacteria through probiotics may not always be beneficial. Similarly, eliminating large groups of foods without a clear reason can lead to unnecessary dietary restriction and reduced nutritional balance.

Restrictive diets may sometimes reduce symptoms temporarily, but they can also reduce the intake of important nutrients such as fibre, vitamins and minerals, all of which support long-term gut and overall health. In addition, overly restrictive eating patterns may deprive the beneficial microbes in the gut of the nutrients they rely on for their normal activity and balance.

A more rational approach is to test first, understand the underlying mechanism, and then treat accordingly. This is where tools such as hydrogen–methane breath testing can provide valuable information5,6.

Breath testing should always be interpreted carefully within the clinical context, to ensure accurate results5,6. It remains the only validated clinical test that provides a functional assessment of microbial fermentation activity in the gut1. Unlike many emerging microbiome analyses, which are currently not standardised or reliable enough to guide treatment decisions, breath testing can help identify patterns such as carbohydrate malabsorption, abnormal fermentation, or possible bacterial overgrowth when used appropriately.

These insights can guide more targeted management rather than trial-and-error approaches, especially, if you are really suffering from the symptoms.

A Note on IBS, Stress and Unexplained Symptoms7

Another important point is that conditions such as irritable bowel syndrome (IBS) must be considered as diagnoses of exclusion. In practice, this means that when major structural or inflammatory diseases have been ruled out, completely, then, symptoms may be grouped under the IBS label.

However, this does not mean the symptoms are imaginary or simply due to stress. While stress can influence gut function, it is often too simplistic to attribute persistent symptoms to psychological factors alone. In practice, almost any symptom can be linked to stress if we stop looking for other explanations! In the same way, many gut symptoms can quickly be labelled as IBS!

In many cases, subtle physiological mechanisms, such as altered gut motility, microbial fermentation, gut hypersensitivity, or food intolerance, may be contributing to symptoms even when routine tests appear normal1. Advances in gut physiology and microbiome research are gradually helping us understand these mechanisms better.

Practical Advice for Hydration and Nutrition Week

For Hydration and Nutrition Week, my message is simple.

  1. Drink fluids regularly throughout the day rather than all at once3.

Use urine colour as a simple guide to hydration.

  • Include fibre in your diet but increase it gradually to avoid developing symptoms2.

Use stool pattern as a simple guide to fibre intake.

  • If you have persisting symptoms despite eating and drinking well, consider whether there may be an underlying reason that deserves further investigation1.

Use Hydrogen-Methane Breath Test as a validated medical grade guide to the root causes.

Digestive symptoms are rarely random. The body always has a reason for them.

In everyday life we already use simple “thermometers” of gut health, urine colour can suggest hydration, and stool patterns can reflect gut movement. At a deeper level, hydrogen–methane breath testing can act as a functional thermometer of microbial activity and your diet in the gut1.

Sometimes, the answers to persistent digestive symptoms can be found not only in what we eat and drink, but also in what our breath quietly reveals about the inner workings of our gut.

This hydration and nutrition week, take control of your gut health. If you are experiencing persistent gut issues, consult a healthcare professional and ask about breath testing. Hydrogen and methane breath testing (HMBT) with devices like the Gastrolyzer® range offer a non-invasive insight into gut health and can aid investigation or diagnosis in a clinical setting or from the comfort of your own home.

To learn more about the Gastrolyzer® range, visit the website here. Dr Jafari’s book ‘The Essential Guide to Hydrogen and Methane Breath Testing’ covers HMBT in detail, if you would like to learn more visit the webpage here.

References:

  1. Jafari J. 2025. The Essential Guide to Hydrogen and Methane Breath Testing: The Modern Non-Invasive Approach to Investigating Gastrointestinal Disorders. Bedfont Scientific Ltd, United Kingdom.
  2. NHS. How to get more fibre into your diet. Available at: https://www.nhs.uk/live-well/eat-well/how-to-get-more-fibre-into-your-diet/ (Accessed: 16th March 2026).
  3. NHS. Water, drinks and your health. Available at:
    https://www.nhs.uk/live-well/eat-well/water-drinks-nutrition/ (Accessed: 16th March 2026).
  4. Yaseen S, Abuelass FK, kamaleldien mohamed Abuelass F. Improving Documentation of Bowel Movements Using the Bristol Stool Chart: A Quality Improvement Project in a District General Hospital in the United Kingdom. Cureus. 2026 Jan 6;18(1).
  5. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S, Schmulson M, Valdovinos M, Zakko S, Pimentel M. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Official journal of the American College of Gastroenterology| ACG. 2017 May 1;112(5):775-84.
  6. Pimentel M, Saad RJ, Long MD, Rao SS. ACG clinical guideline: small intestinal bacterial overgrowth. Official journal of the American College of Gastroenterology| ACG. 2020 Feb 1;115(2):165-78.
  7. National Institute for Health and Care Excellence (NICE). Irritable bowel syndrome in adults: diagnosis and management (CG61). Available at: https://www.nice.org.uk/guidance/cg61 (Accessed: 16th March).
Back to top